Follicular Lymphoma  >>  Tecentriq (atezolizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
LYSA, NCT03276468 / 2016-005061-31: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Completed
2
136
Europe
Atezolizumab, Tecentriq, Obinutuzumab, Gazyvaro, Venetoclax, Venclyxto
The Lymphoma Academic Research Organisation
Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue
09/19
08/22
NCT03465891: Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Terminated
2
2
US
atezolizumab, Low- Dose, Local Radiotherapy
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Lymphoma
12/19
12/19
FLUORO, NCT04962126: Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Active, not recruiting
2
15
RoW
Obinutuzumab 25 MG/1 ML Intravenous Solution, Gazyva, Atezolizumab 1200 MG/40mL Intravenous Solution, Tecentriq, 4 Gy in 2 fractions
Olivia Newton-John Cancer Research Institute, Roche Products Pty Limited, Austin Health, Ballarat Health Services
Follicular Lymphoma
04/23
07/25
NCT02596971 / 2015-001364-19: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Results for Tecentriq in combination with obinutuzumab-bendamustine chemoimmunotherapy regimen for 1L follicular lymphoma
Nov 2022 - Nov 2022: Results for Tecentriq in combination with obinutuzumab-bendamustine chemoimmunotherapy regimen for 1L follicular lymphoma
Checkmark Initiation with atezolizumab in combination with Gazyva and bendamustine for FLL/DLBCL
Nov 2015 - Nov 2015: Initiation with atezolizumab in combination with Gazyva and bendamustine for FLL/DLBCL
Checkmark Initiation in atezolizumab in combination with Gazyva and CHOP for DLBCL
More
Completed
1/2
91
Europe, US, RoW
Atezolizumab, RO5541267; Tecentriq, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, RO5072759, Prednisone, Vincristine, Rituximab
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
04/18
05/20
NCT02729896 / 2015-004845-25: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark First patient in P1/2 trial of Tecentriq + Rituxan + polatuzumab for DLBCL
Jun 2016 - Jun 2016: First patient in P1/2 trial of Tecentriq + Rituxan + polatuzumab for DLBCL
Completed
1/2
36
Europe, US
Atezolizumab [TECENTRIQ], Obinutuzumab, Polatuzumab Vedotin, Rituximab
Hoffmann-La Roche
Lymphoma
09/18
10/19
BO29562, NCT02631577 / 2015-002467-42: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Checkmark Initiation in atezolizumab in combination with Gazyva and lenalidomide for FL/DLBCL
Dec 2015 - Dec 2015: Initiation in atezolizumab in combination with Gazyva and lenalidomide for FL/DLBCL
Completed
1/2
38
Europe, US
Atezolizumab (MPDL3280A) [TECENTRIQ], Lenalidomide, Obinutuzumab
Hoffmann-La Roche
Lymphoma, Follicular
10/18
10/20
NCT05315713: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Completed
1/2
8
Europe, Canada, US, RoW
Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab
Hoffmann-La Roche
Non-Hodgkin Lymphoma, Follicular Lymphoma
07/23
07/23
NP39488, NCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
1/2
280
Europe, US, RoW
Glofitamab, RO7082859, Atezolizumab, Obinutuzumab, Tocilizumab, Actemra, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C
Hoffmann-La Roche
Non-Hodgkins Lymphoma
09/26
09/26

Download Options